Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apololitowereili Monoclonal Antibody plus FLOT in HER2-negative Gastric/GEJ Adenocarcinoma (Neoadjuvant, Phase 2)
ChiCTR2600120362Phase 2Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apololitowereili monoclonal antibody in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fujian Provincial Hospital. Primary endpoint: Pathological Complete Response (pCR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
apololitowereili monoclonal antibody
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600120362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120362.